Ken Griffin Roivant Sciences Ltd. Call Options Transaction History

Citadel Advisors LLC

9 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$10.17 - $12.5 $178,992 - $220,000	-17,600 Reduced 25.36%	51,800 $597,000
Q2 2024 Aug 14, 2024	SELL	$10.36 - $11.74 $288,008 - $326,372	-27,800 Reduced 28.6%	69,400 $733,000
Q1 2024 May 15, 2024	BUY	$9.87 - $11.8 $491,525 - $587,640	49,800 Added 105.06%	97,200 $1.02 Million
Q4 2023 Feb 14, 2024	BUY	$8.38 - $11.58 $150,002 - $207,282	17,900 Added 60.68%	47,400 $532,000
Q3 2023 Nov 14, 2023	SELL	$9.76 - $13.19 $205,936 - $278,309	-21,100 Reduced 41.7%	29,500 $344,000
Q2 2023 Aug 14, 2023	BUY	$7.09 - $10.08 $90,752 - $129,024	12,800 Added 33.86%	50,600 $510,000
Q1 2023 May 15, 2023	SELL	$6.92 - $9.98 $245,660 - $354,290	-35,500 Reduced 48.43%	37,800 $278,000
Q4 2022 Feb 14, 2023	BUY	$3.36 - $7.99 $101,136 - $240,499	30,100 Added 69.68%	73,300 $585,000
Q3 2022 Nov 14, 2022	BUY	$0.51 - $4.84 $15,453 - $146,652	30,300 Added 234.88%	43,200 $139,000

310

507M

1.26M

2.52M

Ticker ROIV
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 704,382,976
Market Cap $8.45B
Description
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.